Author:
Dias Simone Buarque Tavares,Nascimento Ticiano Gomes,Santos Ana Flávia Oliveira,Nicácio Viana Iana Mayane M.,Almeida Rusiene Monteiro,Júnior Irinaldo Diniz Basílio,Macêdo Rui Oliveira,de Araújo-Júnior João Xavier
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. BRASIL, Farmacopéia Brasileira 5ª Edição Vol. 2. Brasília: Df; Dou Nº 224, 24 de novembro de 2010.
2. Manu P, Sarpal D, Muir O, Kane JM, Corell CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012;134:180–6.
3. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.
4. Stahl SM. Antipsychotics and mood stabilizer, third ed. New York: Cambridge University Press, chapter. 45, 2008. In: Rang HP and Dale MM. Farmacologia. 2011; Rio de Janeiro: Elsevier, 768p.
5. Ferrari M, Bolla E, Bortolaso P, Callegari C, Poloni N, Lecchini S, Vender S, Marino F, Cosentino M. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res. 2012;200:1014–7.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献